Stereotactic Body Radiotherapy as a Salvage Therapy after Incomplete Radiofrequency Ablation for Hepatocellular Carcinoma: A Retrospective Cohort Study
Table 1
Baseline characteristics.
Characteristic
No.
%
Total
32
Sex
Male
31
96.9
Female
1
3.1
Age (year)
Median (range)
59.5 (29–80)
Liver disease
HBV
22
68.8
HCV
2
6.2
No virus infection
8
25.0
Anti-HBV therapy
Yes
20
90.9
No
2
9.1
Cirrhosis
Yes
15
46.9
No
17
53.1
Child-Pugh score
5
26
81.3
6
6
18.7
Prior treatments
Median (range)
3 (1–14)
RFA only
11
34.4
RFA and surgery
1
3.1
RFA and TACE
15
47.0
RFA, surgery, and TACE
5
15.5
AFP (ng/ml)
Median (range)
49.9 (1.1–6245.0)
≥200
12
37.5
<200
20
62.5
Tumor diameter (mm)
Median (range)
28 (14–69)
Tumor location†
Perivessels
23
Subcapsular
8
Vessel invasion
Yes
3
9.3
No
29
90.7
Irradiation dose (Gy)
Median (range)
42 (30–54)
BMI, body mass index; HCC, hepatocellular carcinoma; IHC, intrahepatic cholangiocarcinoma; RFA, radiofrequency ablation; TACE, transarterial chemoembolization; AFP, alpha-fetoprotein. † Some lesions can be both perivessel and subcapsular HCCs or neither perivessel nor subcapsular.
